Featured Research

from universities, journals, and other organizations

Penn Researchers Discover Key To How SARS Virus Infects Cells

Date:
August 16, 2005
Source:
University of Pennsylvania School of Medicine
Summary:
Researchers from the University of Pennsylvania School of Medicine have found that inhibitors of an enzyme called cathepsin L prevent the SARS (severe acute respiratory syndrome) virus from entering target cells. This study also demonstrates a new mechanism for how viral proteins are activated within host cells.

A proposed model of how SARS coronavirus enters the host cell. To gain entry, the virus binds to receptors on the cell surface as is taken up into a vesicle (endocytosis). Cathepsin L proteases facilitate fusion of the viral membrane and the vesicle membrane. Credit: Graham Simmons, PhD and Paul Bates, PhD (University of Pennsylvania School of Medicine)

Researchers from the University of Pennsylvania School ofMedicine have found that inhibitors of an enzyme called cathepsin Lprevent the SARS (severe acute respiratory syndrome) virus fromentering target cells. SARS is caused by an emergent coronavirus. Thereis no effective treatment at this time.

This study alsodemonstrates a new mechanism for how viral proteins are activatedwithin host cells, states senior author Paul Bates, PhD, an AssociateProfessor in the Department of Microbiology. Bates and first authorGraham Simmons, PhD, Research Associate, also in the Department ofMicrobiology, published their findings in the early August issue of theProceedings of the National Academy of Sciences.

To gain entry, avirus binds to receptors on the surface of the host cell, and is takenup into a vesicle, or sphere, inside the cell. (Click on thumbnail toview full-size images). Unlike most known viruses, the SARS coronavirus(like the Ebola virus) needs one more step to infect the cell. Theproteins within the membrane of both SARS and Ebola need to be cut byspecial cellular enzymes (cathepsins) in order to replicate within thehost cell. Cathepsins act in the low pH (acidic) environment inside thevesicle, facilitating fusion of the viral membrane and the vesiclemembrane, so that viral proteins and nucleic acids can enter the cellwhere viral replication occurs.

“This paper changes the thinkingof the field,” says Bates. “Up to this point, everyone thought all ofthe activation steps were at the cell surface or due to the low pHenvironment in the vesicle. Our paper shows that it’s not just low pH,but the cathepsin proteases in the vesicles that clip the viralprotein. This gives us a new target to address in the development oftherapeutics against the SARS virus.”

The researchers found thatseveral chemical inhibitors of cathepsin activity blocked infection ofhuman cell lines by the SARS virus, which were grown in a high-levelsafety laboratory. In general, these findings, say the researchers,have led to a better understanding that the cutting of viral protein bycathepsins is necessary for infectivity and is likely not uniquebecause both the SARS and Ebola viruses are now known to use a similarmechanism to invade their host cells. (In June 2005, a group fromHarvard School of Medicine discovered that the Ebola viral membraneprotein is similarly activated by cathepsin L and B.)

If theseproteases are important for other viruses, they represent a new way tostop viral infection. SARS and Ebola are the first examples of the needfor these proteins to be cleaved during infection of the host cell.

Thiswork is a joint collaboration between the Bates lab and the researchgroup led by Scott L. Diamond, PhD, Director of the Penn Center forMolecular Discovery, one of nine facilities that the NationalInstitutes of Health (NIH) is establishing as part of the MolecularLibrary Screening Center Network. Diamond is also Professor of Chemicaland Biomolecular Engineering within the Institute for Medicine andEngineering at Penn. While independently screening for inhibitors,Diamond’s lab found a cathepsin L inhibitor called MDL28170, whichBates and Simmons tested for efficacy in inhibiting SARS coronavirusinfection. The cellular cathepsin enzymes have many other roles withinthe body, including mediating the inflammatory immune response in thelungs and antigen processing in T cells.

The Bates researchgroup, in collaboration with the Diamond group, has identified a fewcompounds, including MDL28170, which they plan to test in animals forSARS inhibition. “We’re now searching for other viruses that also usethis cleaving mechanism for activating their proteins,” says Bates. “Ifthere are a number of other viruses that do that, and we have somepreliminary evidence to suggest this, then we can develop smallmolecule inhibitors as possible therapeutics.” One advantage of thisapproach is that oral medications made from small-molecule inhibitorsare more readily made and distributed in the developing world-asopposed to a vaccine, suggests Bates. Protease inhibitors activeagainst cathepsins have been tested in mice with no ill side effects,which bodes well for their eventual testing in humans.

Co-authorsare Dhaval N. Gosalia, Andrew J. Rennekamp, and Jacqueline D. Reeves,all from Penn. This study was funded by NIH and the NIH Mid-AtlanticRegional Center of Excellence for Biodefense and Emerging InfectiousDiseases.


Story Source:

The above story is based on materials provided by University of Pennsylvania School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of Pennsylvania School of Medicine. "Penn Researchers Discover Key To How SARS Virus Infects Cells." ScienceDaily. ScienceDaily, 16 August 2005. <www.sciencedaily.com/releases/2005/08/050814171056.htm>.
University of Pennsylvania School of Medicine. (2005, August 16). Penn Researchers Discover Key To How SARS Virus Infects Cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/08/050814171056.htm
University of Pennsylvania School of Medicine. "Penn Researchers Discover Key To How SARS Virus Infects Cells." ScienceDaily. www.sciencedaily.com/releases/2005/08/050814171056.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins